Mediterr J Rheumatol 2020;31(2):230-4
Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis
Authors Information
1. Paediatric Immunology and Rheumatology Referral Centre, 1st Paediatric Department, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
2. 4th Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
  1. Leong JY, Guan YJ, Albani S, Arkachaisri T. Recent advances in our understanding of the pathogenesis of juvenile idiopathic arthritis and their potential clinical implications. Expert Rev Clin Immunol 2018;14(11):933-44.
  2. Ceeraz S, Nowak EC, Burns CM, Noelle RJ. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther 2014;16(5):469.
  3. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
  4. Sakkas L, Daoussis D, Mavropoulos A, Liossis SN, Bogdanos DP. Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases. Semin Arthritis Rheum 2019;48(6):1133-41.
  5. Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006;177(12):8844–50.
  6. Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, et al. Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS One 2018;13(2):e0192704.
  7. Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol 2017;188(3):455-66.
  8. Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis Res Ther 2015;17:340.
  9. Greisen SR, Rasmussen TK, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Hvid M, et al. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol 2014;43(2):101-8.
  10. Shenoi S, Ou JN, Ni C, Macaubas C, Gersuk VH, Wallace CA, et al. Comparison of biomarkers for systemic juvenile idiopathic arthritis. Pediatr Res 2015;78(5):554-9.
  11. Cai L, Zhang C, Wu J, Zhou W, Chen T. Decreased PD-1 expression on circulating CD4+T cell and PD-L1 expression on myeloid dendritic cell correlate with clinical manifestations in systemic juvenile idiopathic arthritis. Joint Bone Spine 2019;86(1):61-8.
  12. Zacca ER, Onofrio LI, Acosta CDV, Ferrero PV, Alonso SM, Ramello MC, et al. PD-L1+ Regulatory B Cells are significantly decreased in Rheumatoid Arthritis patients and increase after successful treatment. Front Immunol 2018;9:2241.
  13. Zhao Q, Jung LK. Frequency of CD19+CD24hiCD38hi regulatory B cells is decreased in peripheral blood and synovial fluid of patients with juvenile idiopathic arthritis: a preliminary study. Pediatr Rheumatol Online J 2018;16(1):44.
  14. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2):390-2.
  15. Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 2019;46(2):190-7.
  16. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61(5):658-66.
  17. Vijatov-Djuric G, Doronjski A, Mitic I, Brkic S, Barisic N. Interleukin-17A Levels Increase in Serum of Children With Juvenile Idiopathic Arthritis. Arch Rheumatol 2017;32(3):234-43.